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Abstract: Nitric oxide (NO) production by endothelial nitric oxide synthase (eNOS) plays a protective role in cerebral 
ischemia by maintaining vascular permeability, whereas NO derived from neuronal and inducible NOS is neurotoxic and 
can participate in neuronal damage occurring in ischemia. Matrix metalloproteinases (MMPs) are up-regulated by ischemic 
injury and degrade the basement membrane if brain vessels to promote cell death and tissue injury. We previously reported 
that agmatine, synthesized from L-arginine by arginine decarboxylase (ADC) which is expressed in endothelial cells, has 
shown a direct increased eNOS expression and decreased MMPs expression in bEnd3 cells. But, there are few reports about 
the regulation of eNOS by agmatine in ischemic animal model. In the present study, we examined the expression of eNOS and 
MMPs by agmatine treatment after transient global ischemia in vivo. Global ischemia was induced with four vessel occlusion 
(4-VO) and agmatine (100 mg/kg) was administered intraperitoneally at the onset of reperfusion. The animals were euthanized 
at 6 and 24 hours after global ischemia and prepared for other analysis. Global ischemia led severe neuronal damage in the rat 
hippocampus and cerebral cortex, but agmatine treatment protected neurons from ischemic injury. Moreover, the level and 
expression of eNOS was increased by agmatine treatment, whereas inducible NOS (iNOS) and MMP-9 protein expressions 
were decreased in the brain. These results suggest that agmatine protects microvessels in the brain by activation eNOS as well as 
reduces extracellular matrix degradation during the early phase of ischemic insult.
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hippocampal CA1 pyramidal neurons and cortical neurons 
in the third to fifth layers of the cerebral cortex, starting 2~3 
days after reperfusion (Katsuta et al., 2003). It also induces 
excessive nitric oxide production, a major free radical, which 
causes neuronal death after ischemic injury (Moro et al., 
2004).
Nitric oxide (NO) is a signaling molecule in the central 
nervous system, with functions as a neurotransmitter, as well 
as a regulator of cerebral blood flow (Idecola 1997). NO is 
generated from L-arginine by nitric oxide synthase (NOS). It 
may have both neuroprotective and neurotoxic functions in 
the ischemic brain. NOS can be classified into three groups, 
numbered in the order in which they were cloned. The 
endothelial NOS (eNOS) expressed in the endothelial cells 
Introduction
Transient global ischemia continues to be an important 
clinical problem with limited treatment options (Lo et al., 
2003). It is a consequence of severe arrhythmia, cardiac 
arrest and hemorrhagic shock, leading to a delayed neuronal 
damage in the hippocampus and the cerebral cortex (Kohno 
et al., 1997). Global brain ischemia leads to cell death in Agmatine induced eNOS expression after GI
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and the NO generated by this enzyme, has been suggested 
to have beneficial effects (Raghavan & Dikshit, 2004). eNOS 
not only promotes vascular dilation but also increases 
vascular smooth muscle cell proliferation and migration, and 
thereby enhances arteriogenesis after stroke (Cui et al., 2009). 
Therefore, the regulation of eNOS may play an important 
role in ischemia-reperfusion injury. On the contrary, the 
overproduction of NO by inducible NOS (iNOS) has been 
tightly linked to neuroinflammation and neurodegeneration 
associated with ischemic injury (Moro et al., 2004). It can 
also participate in neuronal damage occurring in the late 
phase of focal ischemia (Iadecola 1997). Agmatine, which 
is synthesized from the decarboxylation of L-arginine by 
arginine decarboxylase (ADC), is capable of inhibiting iNOS 
activity (Blantz et al., 2000; Raasch et al., 2001) and protected 
the neurons from NO induced toxicity by inhibiting its 
production in the microglia (Abe et al., 2000). Agmatine also 
has been shown to exert neuroprotective properties against 
ischemia-hypoxia injury (Feng et al., 2002; Kim et al., 2004; 
Lee et al., 2009; Kim et al., 2010; Mun et al., 2010).
So far data suggest that extracellular pathophysiology may 
also influence cerebral ischemic outcomes. One of evidence 
supporting this idea was the finding that mice deficient 
in tissue plasminogen activator were protected against 
hippocampal injury after kainic acid injections (Tsirka et al., 
1996). It has been shown that another class of extracellular 
proteases, the matrix metalloproteinases (MMPs), may also 
degrade extracellular matrix and trigger anoikis-like cell death 
in neurons (Gu et al., 2002). MMPs comprise an important 
family of proteases associated with basement membrane and 
extracellular matrix remodeling and are involved in both 
physiological and pathological CNS processes (Pagenstecher 
et al., 1998; Yong et al., 1998). In particular, the gelatinases 
(MMP-2 and MMP-9) have been implicated specifically 
in cerebral ischemia (Lo et al., 2002). Recently, it has been 
suggested that MMPs may be upregulated in hippocampus 
after global brain ischemia (Rivera et al., 2002; Zalewska et al., 
2002).
Agmatine was shown to stimulate nitrite formation as 
well as Ca
2＋ uptake in endothelial cells (Joshi et al., 2007). 
It was initially speculated that agmatine might function as 
an alternative substrate for eNOS and contribute towards 
vasodilation by generating NO (Morrissey & Klahr, 1997). We 
previously reported exogenous agmatine treatment attenuated 
the MMP-2 and MMP-9 expression and this expression 
was mediated by the increase of eNOS after oxygen-glucose 
depriviation (OGD) and reperfusion injury in the cerebral 
endothelial cells (Yang et al., 2007). Moreover, agmatine 
treatment decreased the expression of MMP-2 and MMP-
9 after transient focal cerebral ischemia in mice (Kim et al., 
2008). However, changes in regional distribution and the 
timing of eNOS expression by agmatine treatment have not 
been fully characterized, especially during the early time after 
cerebral ischemia/reperfusion.
This study examines the effect of agmatine on the eNOS 
and MMPs levels in rat brain at the immediate (6 h) and 24 
h postischemic periods. A global ischemia model was used 
because it more closely matches the clinical situation in 
humans. We used complementary immunohistochemical and 
immunoblot approaches to characterize the effect of ischemia 
on the parietal cortex and hippocampus.
Materials and Methods
Global ischemia and drug treatment
A total of 22 healthy, adult, specific pathogen-free, male 
Sprague Dawley rats, aged 9~11 weeks and weighing 
300~350 g, were obtained from Sam tako, INC. (Osan, 
Korea). All animal procedures were carried out according 
to a protocol approved by the Yonsei University Animal 
Care and Use Committee, which was in accordance with the 
NIH guidelines. All experiments attempted to minimize the 
number of animals used and their suffering.
Transient global cerebral ischemia was induced with four 
vessel occlusion (4-VO), as described previously (Pulsinelli 
& Brierley, 1979). In brief, animals were anesthetized with 
3% isoflurane and maintained at a level of 2% isoflurane in 
70% N2O and 30% O2 with spontaneous breathing during 
surgery. The skin was incised on the neck and the connective 
tissue and muscles were gently pulled aside. The right and 
left alar foramina of the first cervical vertebrae were exposed, 
and then both vertebral arteries were electrocauterized and 
permanently occluded. On the following day, both common 
carotid arteries (CCA) were occluded with aneurysm clips 
to induce cerebral ischemia for 20 minutes. During surgery 
and for 2 h into the recovery period, rectal temperature was 
controlled at 37±0.5
oC with a feedback-regulated heating 
blanket (Homeothermic Blanket Control Unit, Harvard 
apparatus; Edenbridge, UK). An EEG was monitored to 
ensure isoelectricity after carotid artery occlusion. The 
animals were randomized into three groups including a 
normal control (n=10) and two global ischemic groups: global Anat Cell Biol 43:230~240, 2010 Chin Hee Mun, et al 232
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ischemia with agmatine treatment (Agm, n=6) or without 
agmatine treatment (EC, n=6). The rats in global ischemic 
groups were euthanized at 6, and 24 hours after ischemia.
Agmatine was dissolved in normal saline (100 mg/kg IP, 
Sigma, St Louis, MO, USA) and administered with CCA 
reperfusion. Controls received normal saline in equivalent 
volumes. Dose of agmatine was based on previous experience 
which was shown to be neuroprotective (Feng et al., 2002; 
Kim et al., 2004 and 2010; Kim et al., 2006; Mun et al., 2009).
H-E staining
Histological study was conducted at 6, and 24 hours (n=5/
NC, n=3/EC and Agm per each time point) after reperfusion. 
Animals were perfused transcardially with 200 mL of saline 
followed by 300 mL of 4% paraformaldehyde solution and 
were decapitated. Brains were removed and postfixed in the 
same paraformaldehyde solution for days and then embedded 
in paraffin. Five μm sections were cut through the dorsal 
hippocampus (anteroposterior coordinate, bregma - 3.8 
mm) on a microtome (Microm, Germany). Brain sections 
were stained with hematoxylin-eosin (H&E) and dehydrated 
by immersing in serial ethanol baths, and they were then 
mounted with Vecta Mount (Vector Laboratories Inc, CA, 
USA).
TUNEL staining
Brain sections were immersed in a citric buffer, pH 6.0, 
heated in a microwave oven for 15 min, and labeled with an in 
situ Cell Death Detection Kit (Roche, Indianapolis, IN, USA). 
A mixture of Fluorescein-labeled nucleotides and terminal 
deoxynucleotidyl transferase was applied on sections for 
60 min at 37
oC in a dark humidified chamber as previously 
described (Mun et al., in press). The stains were observed 
under a fluorescence microscope (LSM 510 META, Carl 
Zeíss, Germany).
Western blot analysis
The expressions of eNOS, iNOS and MMPs proteins in 
global cerebral ischemia were estimated by standard protocol 
(Lee et al., 2001). Briefly, the cerebral cortex in rat brains 
was dissected, homogenized to extract cellular proteins with 
a lysis buffer containing 1× PBS, 1% nonidet P-40, 0.5% 
sodium deoxycholate, 0.1% SDS, proteinase inhibitor (PMSF, 
aprotinin and sodium orthovanadate) and centrifuged at 
13,000 rpm for 17 min at 4
oC. The protein concentration 
in the supernatant was determined by the BCA method 
(PIERCE, Rockford, USA). Equal amounts of protein (40 μg) 
per condition were separated on 10% SDS-polyacrylamide 
gel electrophoresis (PAGE) and electrotransferred onto 
Immobilon-NC membranes (Milipore, Bedford, MA, 
USA). Immunoblotting was performed using anti-eNOS 
(Transduction Lab, Hercules, CA, USA; 1 : 1,000), anti- 
iNOS (Chemicon, Temecula, CA, USA; 1 : 5,000), anti- 
MMP-2, -9 (Chemicon Temecula, CA, USA; 1 : 2,000) and 
anti-actin (Santa Cruz Biotech, Santa Cruz, CA, USA; 1 : 
1,000). Immunoreactive bands were visualized with the ECL 
detection system (Amersham Life Science, Buckinghamshire, 
UK) using X-ray film (Kodak, Rochester, NY, USA). Optical 
density of the bands was quantified in a computer-assisted 
image analysis system (NIH Image J), and normalized with 
respect to beta actin.
Immunohistochemistry
Brain sections were rehydrated and immunostained 
with primary antibodies against eNOS (Transduction Lab, 
Hercules, CA, USA; 1 : 500) followed by an appropriate 
biotinylated secondary antibody. Stains were visualized 
using the ABC kit (Vector Laboratories Inc, CA, USA; Lee 
et al., 2001), then reacted with diaminobenzidine (DAB; 
Sigma, St. Louis, USA) as a substrate and counterstained 
with hematoxylin. Images were observed and captured 
on an Olympus AX80 microscope equipped with a DP-70 
digital camera (Olympus, Japan). All incubation steps were 
performed in a humidified chamber.
Cell counts
At 6 and 24 hours, the rats were euthanized with five 
animals per NC, three animals per EC and Agm used for 
cell count study. Brain structures were identified according 
to a standard rat brain atlas (Paxinos & Watson, 1998). 
Sections were prepared through dorsal hippocampus 
(anteroposterior coordinate, bregma - 3.8 mm). All of the data 
for immunohistochemistry were collected from 4 regions, 
which are 2 regions (CA1 sector of both hippocampus, 
magnification ×200), 2 regions (parietal cortex of both 
hemisphere, magnification ×100) per animal. The positive 
cells of eNOS were identified based on stained endothelium 
of vessels and capillaries per each animal. All histological 
preparations were analyzed by a blinded investigator with the 
aid of Image J software (NIH).Agmatine induced eNOS expression after GI
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Statistical analysis
Statistical tests to determine the differences between 
groups were performed with Student’s t-test using the SPSS 
Statistical Software version 13.0 (SPSS, Chicago, IL, USA). 
P-value<0.05 was considered significant. Data were expressed 
as mean±standard deviation (SD).
Results
Neuroprotection by agmatine in brain after transient 
global ischemia
First, hematoxylin and eosin was used to stain the brain 
tissues described in the method to observe pathological 
alterations after global ischemia. And TUNEL staining 
was performed to confirm the patterns of neuronal injury 
observed in the hippocampus.
The results demonstrated that normal neurons had round 
and pale stained nuclei (Fig. 1Aa), whereas dying neurons 
showed pyknotic nuclei in the hippocampus (Fig. 1Ab) and 
had already vacuolated in the parietal cortex (Fig. 1Ah). H-E 
staining showed eosinophilia which is one of the earliest 
histochemical markers of neuronal degeneration after global 
ischemia. In the well-studied hippocampal CA1 region, the 
severity of the neuronal degeneration due to the ischemic 
insults was observed with eosinophilic neurons as early as 6 h 
postischemia (Fig. 1Ab). But in the agmatine treatment group, 
few eosinophilic neurons were observed in the hippocampus 
(Fig. 1Ac). For cortical neurons, many pyramidal neurons 
were observed in the parietal cortex of the control group (Fig. 
1Ag). While marked morphological changes were visualized 
in the untreated group: neuronal loss, nuclei shrinkage, 
neuronal vacuolization, and dark staining of neurons, 
agmatine treatment markedly attenuated these pathological 
changes at 6 h postischemia in the parietal cortex (Fig. 1Ah 
Fig. 1. Neuronal damages in rat hippo-
campus (a~f) and cortex (g~i) at 6 
(A) and 24 h (B) after transient global 
ischemia. H-E and TUNEL staining 
were analyzed for histology, especially 
in the CA1 region of hippocampus and 
in the parietal cortex of cerebral cortex. 
NC, normal control; EC, experimental 
controls without agmatine treatment; 
Agm, agmatine treatment groups. 
Arrows point to necrotic and apoptotic 
neurons compared with the control. 
Scale bar=100 μm.Anat Cell Biol 43:230~240, 2010 Chin Hee Mun, et al 234
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and Ai). Moreover, few TUNEL-positive cells were shown in 
the agmatine treatment group compared with the untreated 
group in the hippocampal CA1 region at 6 h postishcmeia (Fig. 
1Ae and Af).
At 24 h after ischemia the neuronal damage was more 
severe than at 6 h postischemia in both H-E and TUNEL 
staining (Fig. 1Bb, Be and Bh). At this time point cell loss 
and ghost cells were noted in the CA1 hippocampal sector 
and a large population of cortical neurons was also damaged. 
However, agmatine treatment attenuated CA1 cell death and 
cortical neuronal damage at 24 h postischemia compared 
with the untreated group (Fig. 1Bc, Bf and Bi).
Levels of eNOS and iNOS in rat hippocampus
At 6 h after transient global ischemia, eNOS level 
was decreased compared with the control level in the 
hippocampus (Fig. 2A and B). However, agmatine treatment 
increased the ischemia-induced decrease in eNOS at 6 h 
postischemia, by 1.79 fold compared with experimental group 
in the hippocampus. Densitometric data revealed that global 
ischemia induced a significant increase in the eNOS level 
at 24 h, by 1.70 fold compared with 6 h postischemia (Fig. 
2B). Agmatine treatment sustained the increased eNOS level 
during 24 h after global ischemia.
The rats exhibited an increase the level of iNOS at 6 h 
postischemia, by 2 folds in the hippocampus compared with 
the control (Fig. 2C, D). Moreover, iNOS protein levels were 
gradually increased following the reperfusion periods in spite 
of the early phase of ischemia/reperfusion injury. However, 
agmatine treatment decreased iNOS level by 13.35% at 6 h 
and more effectively by 46.3% at 24 h in the hippocampus 
compared with the untreated animals after ischemia.
Levels of eNOS and iNOS in rat cerebral cortex
Endothelial NOS level was also a little decreased compared 
with the control level in the parietal cortex at 6 h postischemia 
(Fig. 3A, B). But, agmatine treatment increased the ischemia-
induced decrease in eNOS by 1.3 fold in the parietal cortex. 
Densitometric data revealed that global ischemia significantly 
induced the eNOS level by 1.44 fold at 24 h after ischemia 
compared with 6 h postischemia (Fig. 3B). Agmatine 
treatment sustained the increased eNOS level by 1.33 fold at 6 
h, but reduced eNOS level by 23.64 % at 24 h compared with 
the untreated global ischemia.
The level of iNOS was increased by 1.55 fold in the parietal 
cortex at 6 h postischemia, compared with the control 
(Fig. 3C, D). It was also gradually increased following the 
reperfusion periods in the cortex similar to the hippocampus. 
Fig. 2. Effects of eNOS and iNOS expression by agmatine treatment following transient global ischemia in rat hippocampus. Representative 
expressional levels of eNOS (A) and iNOS (C) at 6 h after agmatine treatment (100 mg/kg, i.p), and densitometric data (B, D). Data represent 
means±SD for n=5/NC, n=3/EC and Agm group per each time point. *P<0.05, vs. normal control; 
†P<0.05, vs. experimental control at same 
onset of reperfusion. NC, normal control; EC6, at 6 h after reperfusion without agmatine; Agm6, at 6 h after reperfusion with agmatine; EC24, at 
24 h after reperfusion without agmatine; Agm24, at 24 h after reperfusion with agmatine.Agmatine induced eNOS expression after GI
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However, agmatine treatment decreased iNOS level at 6 h and 
significantly reduced the level by 45.5% at 24 h after global 
ischemia in the parietal cortex compared with the untreated 
animals.
eNOS expression after transient global ischemia
In the control rats, eNOS positive cells with nuclear 
staining were localized to blood vessels in the hippocampus 
and parietal cortex (Fig. 4A). Those positive cells were seen 
in the endothelial layers of large vessels and many capillaries, 
especially in the stratum radiatum of the hippocampus and 
the entire parietal cortex. In the ischemia groups, a few 
microvessels, including capillaries and arteriolae, faintly 
expressed eNOS immunoreactivity in the hippocampus (Fig. 
4Ab) and parietal cortex (Fig. 4Ae) at 6 h after CCA occlusion. 
However, agmatine treatment resulted in an increase of eNOS 
immunoreactivity compared with ischemia alone (Fig. 4Ac 
and Af).
At 24 h after transient global ischemia, a number of eNOS 
positive microvessels were observed both in the untreated 
animals and agmatine treatment group (Fig. 4Ah~Ai and 
4Ak~Al). This immunoreactivity was significantly higher 
than at 6 h postischemia. In addition, most microvessels 
expressed more intense eNOS immunoreactivity in the 
agmatine treatment group compared with the untreated 
group (Fig. 4Ai and Al).
Quantitative cell count
Evaluated by counting, the number of eNOS positive 
microvessels per microscopic field was 11.33±5.03 and 20± 
14 in the hippocampus and parietal cortex of the control 
group, respectively (Fig. 4B, C). At 6 h postischemia, a 
few microvessels expressed eNOS immunoreactivity in 
the hippocampus and parietal cortex, but the numbers 
significantly increased by 3.47 fold in the hippocampus and 
2.23 fold in the parietal cortex of the agmatine treatment 
group, compared with the untreated groups.
Marked induction in the number of eNOS positive 
microvessels was found at 24 h after ischemia, 31.67±10.06 
and 104.67±48.21 in the hippocampal CA1 region and 
parietal cortex, respectively. The number of eNOS positive 
mircovessels was a little increased 33.33±14.29 in the 
hippocampus and 118±26.45 in the parietal cortex with the 
agmatine treatment, compared with the untreated groups.
Levels of MMPs in rat hippocampus and cerebral 
cortex
In normal brains, 72 kDa forms of MMP-2 were present 
Fig. 3. Effects of eNOS and iNOS expression by agmatine treatment following transient global cerebral ischemia in rat cerebral cortex. 
Representative expressional levels of eNOS (A) and iNOS (C) at 24 h after agmatine treatment (100 mg/kg, i.p), and densitometric data (B, D). 
Data represent means±SD for n=5/NC, n=3/EC and Agm group per each time point. *P<0.05, vs. normal control; 
†P<0.05, vs. experimental 
control at same onset of reperfusion. NC, normal control; EC6, at 6 h after reperfusion without agmatine; Agm6, at 6 h after reperfusion with 
agmatine; EC24, at 24 h after reperfusion without agmatine; Agm24, at 24 h after reperfusion with agmatine.Anat Cell Biol 43:230~240, 2010 Chin Hee Mun, et al 236
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as well as MMP-9 at a low density in the hippocampus (Fig. 
5A). Significant elevations in MMP-2 were not observed until 
24 h after ischemia whereas MMP-9 level was significantly 
increased until 24 h after ischemia (Fig. 5B). Agmatine 
treatment decreased MMP-9 expression at 24 h in the hippo-
campus after ischemia.
In cerebral cortex after global ischemia, the level of MMP-
2 was increased in ischemic control group as well as MMP-
9 during 24 h after ischemia (Fig. 5C). However, agmatine 
treatment decreased MMP-9 expression at 6 h and maintained 
the level during 24 h in the cerebral cortex after ischemia.
Discussion
In the present study, H-E staining and TUNEL showed 
that agmatine provides a robust histological protection of 
selectively vulnerable hippocampal CA1 region and parietal 
cortex after global ischemia. According to previous reports, 
agmatine treatment reduced infarct sizes (Kim et al., 2004) 
and brain edema at 22 h after 2 h of middle cerebral artery 
occlusion (MCAO) in mice (Kim et al., 2010), and also 
protected neurons in cortical layer III~V cortex following 
global ischemia (Mun et al., 2010) and this result consistent 
with other reports.
Agmatine, formed by the decarboxylation of L-arginine 
by ADC, has been shown to exert certain neuromodulatory 
functions in the central nervous system (Li et al., 1994). Being 
structurally similar to arginine, agmatine may protect the 
brain from ischemic injury by interfering with nitric oxide 
signaling. Agmatine has been shown to be a competitive 
inhibitor of both neuronal NOS (nNOS) and iNOS (Auguet 
et al., 1995), but the relationship between agmatine and 
endothelial cells to synthesize NO, where NO is a vasodilator 
in cultured endothelial cells (Morrissey & Klahr, 1997) has 
not been clearly elucidated. During ischemia reperfusion 
injury, NO produced mainly by eNOS is known to play an 
Fig. 4. Photomicrographs of eNOS expression by agmatine treatment (A) and quantification of eNOS positive cells (B, C) in rat brain after global 
ischemia. Representative expressional levels of eNOS in bregman - 3.8 mm of naïve rats at 6 and 24 h after agmatine treatment (A). The number 
of eNOS positive cells in the CA 1 sector of hippocampus (B) and in the parietal region of the cerebral cortex (C). Data represent means±SD 
for n=5/NC, n=3/EC and Agm group per each time point. *P<0.05, vs. normal control; 
†P<0.05, vs. experimental control at same onset of 
reperfusion. NC, normal control; EC6, at 6 h after reperfusion without agmatine; Agm6, at 6 h after reperfusion with agmatine; EC24, at 24 h 
after reperfusion without agmatine; Agm24, at 24 h after reperfusion with agmatine; SO, stratum oriens; SP, stratum pyramidale; SR, stratum 
radiatum; HiF, hippocampal fissure. Higher magnifications of cells indicated by squares show eNOS positive cells in the endothelium of vessels 
and capillaries. Arrows point to positive cells that showed higher intensity of immunostaining with hematoxylin in rat brain, compared with the 
control. Scale bar=50 μm (hippocampus), and 100 μm (cortex).Agmatine induced eNOS expression after GI
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important role in the regulation of vascular reactivity, and 
exerts a protective role within the vascular system by its 
vasodilatory effect. A NO-dependent delayed vasodilation 
has been observed 12 to 24 hours after cerebral hypoxic 
ischemia in fetal sheep, and a blockade of this response is 
correlated with increased cellular injury (Marks et al., 1996). 
Moreover, in adult models of focal cerebral ischemia, early 
exposure to NO donors appears to attenuate injury, whereas 
infarct size is enlarged in eNOS-deficient mice (Atochin 
et al., 2003). A rapid increase in eNOS level is consistent 
with the potential beneficial role of this enzyme during the 
initial recovery period after transient global ischemia. In 
addition, it was initially speculated that agmatine might 
function as an alternative substrate for eNOS and contribute 
towards relaxation (Santhanam et al., 2007). We previously 
demonstrated that agmatine induced the expression of 
eNOS and appeared to act directly on endothelial cells to 
increase the synthesis of NO in cerebral endothelial cells 
after OGD or ischemic-like injury (Yang et al., 2007). In 
the present study, a significant increase in eNOS levels was 
observed at 6 h after global cerebral ischemia with agmatine 
treatment both in rat hippocampus and parietal cortex. Using 
immunohistochemical study, which is a semiquantitative 
technique, the eNOS level has been reported to increase 
rapidly in the cerebral cortex and striatum after focal cerebral 
ischemia in rodents (Veltkamp et al., 2002). In our study, the 
number of eNOS positive microvessels were increased both 
6 and 24 h after 4-VO occlusion with agmatine treatment. 
However, the physiologic significance of this selective increase 
of eNOS is unclear. We present evidence that agmatine 
activates eNOS expression in the early time of ischemia/
reperfusion injury in the in vivo model.
In contrast, iNOS has been implicated as an important 
mediator of inflammatory responses during ischemia and 
reperfusion (Moro et al., 2004). Induction of iNOS results in 
delayed neuronal cell death and also exacerbates glutamate 
toxicity (Huang 2004). Also, NO derived from iNOS and its 
oxidative byproduct peroxynitrite are thought to contribute 
to neuronal death occurring in the late phase of cerebral 
ischemia (Iadecola 1997; Pannu & Singh, 2006). According to 
our previous studies, agmatine treatment reduced the number 
of iNOS immunopositive cells in a mouse model of transient 
focal cerebral ischemia (Kim et al., 2004) as well as transient 
global ischemia in the hippocampal CA1 region (Mun et al., 
2009) and cerebral cortex (Mun et al., 2010). However, the 
protein level of iNOS was not investigated at the early time 
Fig. 5. Regulations of MMPs expression by agmatine treatment following transient global ischemia in rat brain. Representative expressional levels of 
MMP-2 and MMP-9 6 and 24 h after agmatine treatment (100 mg/kg, i.p) in the hippocampus (A), in the cerebral cortex (C), and densitometric 
data (B, D). Data represent means±SD for n=5/NC, n=3/EC and Agm group per each time point. *P<0.05, vs. normal control. NC, normal 
control; EC6, at 6 h after reperfusion without agmatine; Agm6, at 6 h after reperfusion with agmatine; EC24, at 24 h after reperfusion without 
agmatine; Agm24, at 24 h after reperfusion with agmatine.Anat Cell Biol 43:230~240, 2010 Chin Hee Mun, et al 238
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of transient global cerebral ischemia in our previous report. 
During ischemia and reperfusion, the expression of NOSs 
and the level of NO production by eNOS and iNOS can be 
regulated differentially in neurons and endothelial cells. In 
addition, the time course of NOS isoform activity shows to 
be delicately controlled and reliant on the period of ischemic 
injury. In this study, global ischemia resulted in an increase of 
iNOS protein level during 24 h. However, agmatine treatment 
decreased iNOS level since 6 h and significantly at 24 h 
postischemia both in the hippocampus and parietal cortex. 
Agmatine modulates iNOS expression after global ischemia 
even though at the early time of injury. Briefly, agmatine 
treatment induces the expression of eNOS and lessens iNOS 
expression in the early phase of cerebral ischemia.
We previously reported agmatine inhibits MMP-2 and 
MMP-9 expression via eNOS in cerebral endothelial cells 
(Yang et al., 2007). In addition, we suggested that exogenous 
and retrovirus induced endogenous agmatine inhibited MMP-
2 and MMP-9 protein expression mediated by eNOS, NO and 
ATF3 expression in brain capillary endothelial cells (Jung et 
al., 2010). We also observed a decrease of MMP-9 expression 
with agmatine treatment in the hippocampus and cortex 
after transient global ischemia in the present study. The above 
results were in well corroboration with our previous findings 
in vitro (Yang et al., 2007; Jung et al., 2010). A role for MMPs 
in brain injury after focal ischemia and trauma has been 
proposed to maintaining the vascular extracellular matrix, a 
constituent of the basal lamina constructing the integrity of 
blood brain barrier (BBB) (Yong et al., 1998; Lo et al., 2002; 
Rosenberg 2002). MMPs, especially MMP-2 and MMP-9, 
degrade the basal lamina that surrounds the cerebral blood 
vessels in ischemic condition. At least in mouse systems, a 
dominant role has been ascribed to MMP-9 because MMP-9 
knock-out mice were protected against ischemia and trauma 
(Wang et al., 2000; Asahi et al., 2001b), whereas MMP-2 
knock-out mice were not protected (Asahi et al., 2001a). Here 
we demonstrated that MMP-9 is upregulated in postischemic 
hippocampus and cerebral cortex even though the expression 
of MMP-2 is not significant versus MMP-9 against global 
ischemic insult.
Our study demonstrated that an exogeneous agmatine 
treatment produced neuroprotection after transient global 
ischemia. However, it was administered without agmatine 
in a critical time for the development of cell death program, 
which starts acutely after global ischemia. Therefore, it seems 
that the application of agmatine treatment in the acute post-
ischemic phase may be both required and sufficient for the 
therapeutic effect.
The question remains as to whether NOS-derived NO 
is eNOS-dominant, nNOS-dominant or iNOS-dominant 
after ischemia/reperfusion injury. A rapid increase in eNOS 
levels is consistent with the potential beneficial role of this 
enzyme during the initial recovery period after transient 
global ischemia. Thus, future studies should seek to define the 
stimulatory effect of agmatine on eNOS and the regulation 
of vascular homeostasis. Determination of the therapeutic 
window of opportunity for agmatine after transient global 
ischemia also warrants further investigation.
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